Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies
<b>Background/Objectives:</b> For several decades, protein drugs (biologics) made in cell cultures have been delivered as sterile injections, decreasing their affordability and patient preference. Angiotensin Converting Enzyme 2 (ACE2) gum is the first engineered human blood protein expr...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/1/12 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832587724690817024 |
|---|---|
| author | Henry Daniell Geetanjali Wakade Smruti K. Nair Rahul Singh Steven A. Emanuel Barry Brock Kenneth B. Margulies |
| author_facet | Henry Daniell Geetanjali Wakade Smruti K. Nair Rahul Singh Steven A. Emanuel Barry Brock Kenneth B. Margulies |
| author_sort | Henry Daniell |
| collection | DOAJ |
| description | <b>Background/Objectives:</b> For several decades, protein drugs (biologics) made in cell cultures have been delivered as sterile injections, decreasing their affordability and patient preference. Angiotensin Converting Enzyme 2 (ACE2) gum is the first engineered human blood protein expressed in plant cells approved by the FDA without the need for purification and is a cold-chain and noninvasive drug delivery. This biologic is currently being evaluated in human clinical studies to debulk SARS-CoV-2 in the oral cavity to reduce coronavirus infection/transmission (NCT 0543318). <b>Methods:</b> Chemistry, manufacturing, and control (CMC) studies for the ACE2/Ang(1–7) drug substances (DSs) and ACE2 gum drug product (DP) were conducted following USP guidelines. GLP-compliant toxicology studies were conducted on Sprague Dawley rats (<i>n</i> = 120; 15/sex/group) in four groups—placebo, low (1.6/1.0 mg), medium (3.2/2.0 mg), and high (8.3/5.0 mg) doses IP/kg/day. Oral gavage was performed twice daily for 14 days (the dosing phase) followed by the recovery phase (35 days). Plasma samples (<i>n</i> = 216) were analyzed for the product Ang(1–7) by ELISA. <b>Results:</b> The ACE2 protein was stable in the gum for at least up to 78 weeks. The toxicology study revealed the dose-related drug delivery to the plasma and increases in the AUC (56.6%) and Cmax (52.9%) after 28 high-dose gavages (95% C.I.), although this quantitation excludes exogenously delivered membrane-associated ACE2/Ang(1–7). Vital biomarkers and organs were not adversely affected despite the 10-fold higher absorption in the tissues, demonstrating the safety for the first in-human clinical trials of ACE2/Ang(1–7). The NOAEL observed in the rats was 2.5–7.5-fold higher than that of the anticipated efficacious therapeutic dose in humans for the treatment of cardiopulmonary disorders, and it was 314-fold higher than the NOAEL for topical delivery via chewing gum. <b>Conclusions:</b> This report lays the foundation for the regulatory process approval for noninvasive and affordable human biologic drugs bioencapsulated in plant cells. |
| format | Article |
| id | doaj-art-94a512c9b5f142a5a082641e18144ba1 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-94a512c9b5f142a5a082641e18144ba12025-01-24T13:45:34ZengMDPI AGPharmaceutics1999-49232024-12-011711210.3390/pharmaceutics17010012Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology StudiesHenry Daniell0Geetanjali Wakade1Smruti K. Nair2Rahul Singh3Steven A. Emanuel4Barry Brock5Kenneth B. Margulies6Department of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Basic & Translational Sciences, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USADepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA<b>Background/Objectives:</b> For several decades, protein drugs (biologics) made in cell cultures have been delivered as sterile injections, decreasing their affordability and patient preference. Angiotensin Converting Enzyme 2 (ACE2) gum is the first engineered human blood protein expressed in plant cells approved by the FDA without the need for purification and is a cold-chain and noninvasive drug delivery. This biologic is currently being evaluated in human clinical studies to debulk SARS-CoV-2 in the oral cavity to reduce coronavirus infection/transmission (NCT 0543318). <b>Methods:</b> Chemistry, manufacturing, and control (CMC) studies for the ACE2/Ang(1–7) drug substances (DSs) and ACE2 gum drug product (DP) were conducted following USP guidelines. GLP-compliant toxicology studies were conducted on Sprague Dawley rats (<i>n</i> = 120; 15/sex/group) in four groups—placebo, low (1.6/1.0 mg), medium (3.2/2.0 mg), and high (8.3/5.0 mg) doses IP/kg/day. Oral gavage was performed twice daily for 14 days (the dosing phase) followed by the recovery phase (35 days). Plasma samples (<i>n</i> = 216) were analyzed for the product Ang(1–7) by ELISA. <b>Results:</b> The ACE2 protein was stable in the gum for at least up to 78 weeks. The toxicology study revealed the dose-related drug delivery to the plasma and increases in the AUC (56.6%) and Cmax (52.9%) after 28 high-dose gavages (95% C.I.), although this quantitation excludes exogenously delivered membrane-associated ACE2/Ang(1–7). Vital biomarkers and organs were not adversely affected despite the 10-fold higher absorption in the tissues, demonstrating the safety for the first in-human clinical trials of ACE2/Ang(1–7). The NOAEL observed in the rats was 2.5–7.5-fold higher than that of the anticipated efficacious therapeutic dose in humans for the treatment of cardiopulmonary disorders, and it was 314-fold higher than the NOAEL for topical delivery via chewing gum. <b>Conclusions:</b> This report lays the foundation for the regulatory process approval for noninvasive and affordable human biologic drugs bioencapsulated in plant cells.https://www.mdpi.com/1999-4923/17/1/12biologicoral drug deliveryAngiotensin Converting Enzyme 2CMCtoxicology |
| spellingShingle | Henry Daniell Geetanjali Wakade Smruti K. Nair Rahul Singh Steven A. Emanuel Barry Brock Kenneth B. Margulies Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies Pharmaceutics biologic oral drug delivery Angiotensin Converting Enzyme 2 CMC toxicology |
| title | Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies |
| title_full | Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies |
| title_fullStr | Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies |
| title_full_unstemmed | Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies |
| title_short | Evaluation of Biologics ACE2/Ang(1–7) Encapsulated in Plant Cells for FDA Approval: Safety and Toxicology Studies |
| title_sort | evaluation of biologics ace2 ang 1 7 encapsulated in plant cells for fda approval safety and toxicology studies |
| topic | biologic oral drug delivery Angiotensin Converting Enzyme 2 CMC toxicology |
| url | https://www.mdpi.com/1999-4923/17/1/12 |
| work_keys_str_mv | AT henrydaniell evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT geetanjaliwakade evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT smrutiknair evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT rahulsingh evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT stevenaemanuel evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT barrybrock evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies AT kennethbmargulies evaluationofbiologicsace2ang17encapsulatedinplantcellsforfdaapprovalsafetyandtoxicologystudies |